174 related articles for article (PubMed ID: 33376084)
1. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
[TBL] [Abstract][Full Text] [Related]
2. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
[TBL] [Abstract][Full Text] [Related]
3. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
[TBL] [Abstract][Full Text] [Related]
4. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
[TBL] [Abstract][Full Text] [Related]
5. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
Levin PA; Wei W; Zhou S; Xie L; Baser O
J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
[TBL] [Abstract][Full Text] [Related]
7. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
Abusnana S; Al Awadi F; Aly H; Bashier A; Kumar Dhanwal D; Halasa T; Jallo M; Medina J; Singhal S
Diabetes Res Clin Pract; 2023 Feb; 196():110183. PubMed ID: 36436550
[TBL] [Abstract][Full Text] [Related]
8. Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
Hoog M; Smith JL; Yu M; Peleshok J; Mody R; Grabner M
Clin Ther; 2022 Jun; 44(6):873-887. PubMed ID: 35618571
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.
Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C
Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039
[TBL] [Abstract][Full Text] [Related]
10. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
Maegawa H; Ishigaki Y; Langer J; Saotome-Nakamura A; Andersen M;
J Diabetes Investig; 2021 Mar; 12(3):374-381. PubMed ID: 32643314
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.
Conget I; Mauricio D; Ortega R; Detournay B;
BMJ Open; 2016 Jul; 6(7):e010197. PubMed ID: 27466235
[TBL] [Abstract][Full Text] [Related]
12. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
[TBL] [Abstract][Full Text] [Related]
13. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
[TBL] [Abstract][Full Text] [Related]
14. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
Levin PA; Zhou S; Gill J; Wei W
J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
[TBL] [Abstract][Full Text] [Related]
16. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
[TBL] [Abstract][Full Text] [Related]
17. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
[TBL] [Abstract][Full Text] [Related]
18. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
[TBL] [Abstract][Full Text] [Related]
19. The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study.
Fang HSA; Gao Q; Tan WY; Lee ML; Hsu W; Tan NC
BMC Med; 2022 Jan; 20(1):22. PubMed ID: 35078484
[TBL] [Abstract][Full Text] [Related]
20. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
